Greenberg Traurig LLP issued the following announcement on Jan. 15.
For the sixth consecutive year, Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group hosted two events coinciding with the JP Morgan Healthcare Conference in San Francisco.
On Jan. 14 the group presented the lunchtime panel discussion, “Insiders’ Views of Deal Makings,” where seasoned executives from leading life sciences companies shared current trends, best practices, and pitfalls of deals including M&A, licensing, joint ventures, and strategic collaborations. They also shared predictions on what 2020 will hold for deal making.
Panelists included:
Debbie Alexander, Director, Business Development, 23andMe
Shaun Grady, Senior VP, Business Development Operations, AstraZeneca
Dr. Robert Mittendorff, Partner, Norwest Venture Partners
Jeremy Sohn, Vice President, Global Head of Digital Business Development & Licensing, Novartis
The panel was moderated by Fiona Adams, co-chair of Greenberg Traurig’s Global Corporate Practice and managing shareholder of the London office, and Wayne H. Elowe, co-chair of the firm’s global Life Sciences & Medical Technology Group and the Atlanta office Corporate Practice. David J. Dykeman, patent attorney and co-chair of the global Life Sciences & Medical Technology Group and Boston office Intellectual Property & Technology Group, gave opening remarks.
The program was preceded by a private wine tasting and networking reception on Jan. 13, attended by more than 300 health care industry executives and investors.
In addition, Kate Black, a shareholder in the firm’s Data, Privacy & Cybersecurity Practice in the Miami office, introduced companies at the Biotech Showcase on Jan. 14.
Original source can be found here.